ArticleInfection and immunity2005
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 166 citations in OpenAlex.
- Dynamics associated with the efflux pumps in biofilms and persister cells ofMicrobiology spectrum · 2026Article
- Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Pathogenicity and virulence of Cryptococcus neoformans from an environmental perspective.Virulence · 2025Review
- Riboflavin inhibits growth and reduces virulence ofVirulence · 2025Article
- Reduced growth and biofilm formation at high temperatures contribute to Cryptococcus deneoformans dermatotropism.Disease models & mechanisms · 2025Article
- Insights from Mass Spectrometry-Based Proteomics onJournal of fungi (Basel, Switzerland) · 2025Review
- Fungal biofilms in human health and disease.Nature reviews. Microbiology · 2025Review
- Uncovering the antifungal potential of Cannabidiol and Cannabidivarin.PLoS neglected tropical diseases · 2025Article
- Monoclonal antibodies targeting Candida disrupt biofilms and inhibit growth across global clinical isolates.iScience · 2025Article
- Exploring the female genital tract mycobiome in young South African women using metaproteomics.Microbiome · 2025Article
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Peptides fromFuture microbiology · 2025Article
- Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025Review
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Article
- The buoyancy of cryptococcal cells and its implications for transport and persistence ofmSphere · 2024Article
- The buoyancy of cryptococcal cells and its implications for transport and persistence ofbioRxiv : the preprint server for biology · 2024Article
- Naphthylthiazoles: a class of broad-spectrum antifungals.RSC medicinal chemistry · 2023Article
- Assessing the In Vitro Potential of Glatiramer Acetate (CopaxoneJournal of fungi (Basel, Switzerland) · 2023Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
One of the most troublesome medical problems today is infection of prosthetic devices with organisms that form polysaccharide biofilms. This combined with increasing antimicrobial drug resistance is making many infectious diseases incurable. Cryptococcus neoformans is a human-pathogenic fungus that has a polysaccharide capsule and can form biofilms in prosthetic medical devices. We developed a system to study cryptococcal biofilm formation in vitro and studied the effect of antibody to the C. neoformans capsular polysaccharide on this process. C. neoformans biofilm formation was dependent on the presence of a polysaccharide capsule and correlated with the ability of capsular polysaccharide to bind the polystyrene solid support. Protective antibodies prevented biofilm formation whereas nonprotective antibodies were not effective. The mechanism of antibody action involved interference with capsular polysaccharide release from the fungal cell. In contrast, lactoferrin, an effector molecule of innate immune mechanisms, was unable to prevent fungal biofilm formation despite its efficacy against bacterial biofilms. Our results suggest a new role of adaptive humoral immunity whereby some antibodies can inhibit biofilm formation by encapsulated organisms. Vaccines that elicit antibody responses to capsular antigens and/or passive transfer of antibodies to microbial polysaccharides may be useful in preventing biofilm formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.